Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDUnderdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult PatientsA systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatmentBupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adultsTreatment of adults with attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderDoes mindfulness meditation improve attention in attention deficit hyperactivity disorder?Specialist adult ADHD clinics in East Anglia: service evaluation and audit of NICE guideline complianceAssociations of sleep disturbance with ADHD: implications for treatmentPharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature reviewPharmacological treatment of adult ADHD in EuropeSafety of therapeutic methylphenidate in adults: a systematic review of the evidenceAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementThe identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agenciesDifferences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands.Functional consequences of attention-deficit hyperactivity disorder on children and their families.British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.Electrophysiological evidence for abnormal preparatory states and inhibitory processing in adult ADHD.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.Implementation of independent nurse prescribing in UK mental health settings: focus on attention-deficit/hyperactivity disorder.Occupational issues of adults with ADHD.Sleep disturbances in children with attention-deficit/hyperactivity disorderThe occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesMultiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with nA rating measure of ADHD-related neuropsychological impairment in children and adolescents: Data from the Cognition and Motivation in Everyday Life (CAMEL) Scale from population and clinical samples.Clinical service use as people with Attention Deficit Hyperactivity Disorder transition into adolescence and adulthood: a prospective longitudinal study.Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network.Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.Treatment of adult ADHD: is current knowledge useful to clinicians?Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine.Dose of Methylphenidate during Service Transition for Adults with ADHDLimits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.Current issues around the pharmacotherapy of ADHD in children and adults.Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.
P2860
Q21260332-1010068E-E5A8-4163-ADDB-7E88AEDF4DF2Q22241098-9084BF8C-A8E5-4F7D-AA94-5750E5043608Q22241759-51106FCA-530B-477F-8331-1EE9D98882C7Q24234795-07ED821B-7D0F-44C3-B154-B9D99731D2D2Q24642937-779C07C9-5FA3-4FC5-BA3A-EBAFB0BA50BAQ24644586-BD256D55-AA6B-46B9-9FA6-FC3E5F5AD10CQ26770326-54126330-2957-452A-9F26-62A320F105B2Q26801884-6BF25B7F-A70F-45C8-851C-08341BD980C9Q27027062-1CACF57D-1508-4596-A7B4-F24DD15D53DDQ27687469-469CFBFC-8ADF-415F-93FE-2BFAD2D64318Q28243209-73645DC1-F405-444F-91AC-2DEB64CF517BQ28247634-0A22ED07-643D-466C-9986-BBB0476E0303Q28282264-88890AB0-A7B9-40F7-BC57-D5087C202349Q28295525-5CDA5E48-D386-4708-86B5-C57028491C1CQ28742126-E7C3E133-761A-43AF-A978-E742BDA1C156Q29353662-7896D001-BA96-4DCE-98FE-BEB0D89CD75EQ30251626-84310C38-5183-413D-B09B-80803292D4BDQ34135759-39A773CB-6AA3-4FAF-8608-AAFE69F1C2B2Q34308907-EA30163C-00C0-4D46-9780-4BEDDB42C6CAQ34335238-002938D7-7087-4E85-B9C3-578F0C537D03Q34461113-C5100607-A24D-4A26-A7E4-5760940C90CCQ34502493-1B9C2A41-D08B-48F3-928C-8DC7A13C1253Q34505285-AAB3690A-2F80-4CA6-BDF0-9183334FBF57Q34518522-02B0FABB-7EAD-4A08-87CB-BA177FEBB682Q34567343-2ABA29EB-7DE1-433B-BEF5-E9A458AE3781Q34588668-85A07C27-18DC-449E-93FB-DE694391DF88Q35086494-A8540C9D-B59F-4A84-AFEE-D8BCDF3A39E4Q35666363-BE5BD09C-584E-42B6-B050-5532EB9DDD60Q35755924-ED690B96-143F-4B5A-AAB9-E49E0A299A84Q35866330-88729A7E-FA74-44B8-BF6E-E5A8AD5DEAEFQ35993998-5BCDB35C-27B4-4BF5-B8F7-A2D0231F2B60Q36072889-135C49E5-AEC7-48B8-AF31-38899FDE41AEQ36113283-84F29E34-881F-45C0-89F3-4B425BF79DB7Q36757388-0E69CA90-C6C1-4B51-A7E5-051FF3B8E331Q36836781-9B26B3C0-7EA7-4B7E-B828-081CC22A23CCQ36858837-AD61CF43-3878-4664-AA3B-27A10EFE98ADQ37078924-F52304B3-5EFB-452E-97A4-7369ED40F85BQ37194205-C498FEC7-8D2A-4D73-8C48-9C190B775ACFQ37314533-4A47C44E-E839-4A95-9703-AF24A01701D0Q37318744-C9F9F3BD-7CCE-4CC1-80ED-7AC34D9F6D97
P2860
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
type
label
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
prefLabel
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
P2093
P2860
P50
P356
P1476
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
P2093
British Association for Psychopharmacology
E Sonuga-Barke
K A Morris
P Asherson
P2860
P356
10.1177/0269881106073219
P407
P577
2006-11-08T00:00:00Z